Imagine losing 15% of your body weight and still feeling judged — not for failing, but for succeeding the wrong way. A new study published in the journal Stigma & Health reveals that women who shed pounds using GLP-1 medications like Ozempic or Wegovy face significantly more social stigma than those who lose the same weight through diet and exercise alone. The research, led by social psychologist Stacy Post, Ph.D., a postdoctoral researcher at Georgetown University's Lombardi Comprehensive Cancer Center, exposes a troubling gap between the medical legitimacy of these drugs and how society perceives them.
More than 100 million people in America are clinically eligible to use GLP-1 medications, and approximately 18% of U.S. adults have already used or are currently using one. For millions of people managing obesity — a chronic condition linked to increased risks of cancer, diabetes, and heart disease — these medications can be transformative. Yet Post's research suggests that many who benefit from them carry an invisible burden: shame.
"GLP-1 medications can offer meaningful health benefits for people with obesity, but many patients report feeling shame and guilt for using them," Post said. "Our results show that the 'easy way out' perception does more than spark casual criticism. It can translate into measurable stigma, including fat phobia and a desire for social distance."
To test these dynamics, Post and her colleagues recruited 402 U.S. women ages 30 to 49 who identified as either Black or white and who also reported being overweight or living with obesity. Participants were randomly assigned to read a brief scenario about a woman named Evette who lost 15% of her body weight either through diet and exercise or with a GLP-1 medication. Evette was depicted as either a Black woman or a white woman using pre-tested photographs. Participants then rated Evette on several stigma-related dimensions, including fat phobia, dislike, blame, and desire for social distance.
The results were striking. Evette faced measurably higher stigma when she lost weight with a GLP-1 medication rather than through lifestyle changes alone. The researchers found that beliefs about GLP-1-assisted weight loss being an unfair shortcut predicted higher fat phobia, greater dislike, more blame, and increased desire for social distance. Interestingly, stigma was also higher when Evette was portrayed as a white woman rather than a Black woman — a finding that warrants further exploration, though the race of the study participants themselves did not significantly influence stigma outcomes.
The implications extend beyond social discomfort. Weight stigma is associated with harmful health outcomes, including stress, depression, anxiety, and negative health behaviors. Post and her colleagues warn that GLP-1-related stigma may discourage people from seeking evidence-based care or intensify shame for those already managing a chronic condition.
"Treatment decisions should be guided by health, not judgments about how someone manages their weight," Post said. The researchers are now calling for communication strategies that better explain how GLP-1 medications work biologically, emphasize positive health outcomes, and reduce the perception that medication-assisted weight loss is inherently less legitimate than lifestyle approaches alone. In doing so, they hope the conversation shifts from one of willpower and shortcuts to one of compassion and clinical reality.